Delving into the Latest Updates on Beijing Danqing Pharmaceutical Technology Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Urogenital Diseases

Digestive System Disorders

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	5
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	5

Top 5 Target	Count

PARG(Poly(ADP-ribose) glycohydrolase)	2
WRN(WRN RecQ like helicase)	1
POLQ(DNA polymerase theta)	1

[Translation] A dose-escalation, dose-expansion, open-label, Phase I study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of DAT-2645 in patients with advanced/metastatic solid tumors harboring BRCA1/2 loss-of-function mutations and/or other defects in the DNA damage repair (DDR) pathway

本研究主要目的为评估PARG抑制剂DAT-2645在携带BRCA1/2功能缺失突变和/或DDR通路中其他缺陷的晚期或转移性实体瘤中的安全性、耐受性、PK、PD指标及初步临床疗效，确定MTD和RP2D，为后续开展临床试验提供I期临床试验数据。

[Translation]

The main purpose of this study is to evaluate the safety, tolerability, PK, PD indicators and preliminary clinical efficacy of the PARG inhibitor DAT-2645 in advanced or metastatic solid tumors carrying BRCA1/2 loss-of-function mutations and/or other defects in the DDR pathway, determine the MTD and RP2D, and provide Phase I clinical trial data for subsequent clinical trials.

Start Date-

Sponsor / Collaborator

Beijing Danqing Pharmaceutical Technology Co., Ltd.

NCT06614751

/ Not yet recruitingPhase 1

A Phase I, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of DAT-2645 in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DNA Damage Repair Pathway

The primary objective of the study is to evaluate the safety, tolerability, PK, PD, and prilimary efficacy of a PARG inhibitor DAT-2645 in patients with advanced/metastatic solid tumors harboring BRCA1/2 loss of function alterations and/or other defects in the DNA damage repair (DDR) pathway.

Start Date01 Nov 2024

Sponsor / Collaborator

Beijing Danqing Pharmaceutical Technology Co., Ltd.

100 Clinical Results associated with Beijing Danqing Pharmaceutical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Danqing Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Deals associated with Beijing Danqing Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Danqing Pharmaceutical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

3

2

Phase 1 Clinical

Other

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

DAT-2645 ( PARG )	Breast Cancer More	Phase 1
DAT-2000 ( PARG )	Solid tumor More	Phase 1
DAT-6000	Solid tumor More	Preclinical
DAT-1000 ( POLQ )	Female Genital Neoplasms More	Preclinical
DAT-5000 ( WRN )	Solid tumor More	Preclinical